3-(2-anilino-3-methylbenzimidazol-5-yl)-6-chloro-N-(cyclopropylmethyl)imidazo[1,2-b]pyridazin-8-amine
C24H22ClN7 — CID 155560538
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-(2-anilino-3-methylbenzimidazol-5-yl)-6-chloro-N-(cyclopropylmethyl)imidazo[1,2-b]pyridazin-8-amine
3-(2-anilino-3-methylbenzimidazol-5-yl)-6-chloro-N-(cyclopropylmethyl)imidazo[1,2-b]pyridazin-8-amine (PubChem CID 155560538) has the molecular formula C24H22ClN7 and a molecular weight of 443.94 g/mol. Its IUPAC name is 3-(2-anilino-3-methylbenzimidazol-5-yl)-6-chloro-N-(cyclopropylmethyl)imidazo[1,2-b]pyridazin-8-amine.
Molecular Properties
| Compound Name | 3-(2-anilino-3-methylbenzimidazol-5-yl)-6-chloro-N-(cyclopropylmethyl)imidazo[1,2-b]pyridazin-8-amine |
|---|---|
| PubChem CID | 155560538 |
| Molecular Formula | C24H22ClN7 |
| Molecular Weight | 443.94 g/mol |
| Exact Mass | 443.16 |
| IUPAC Name | 3-(2-anilino-3-methylbenzimidazol-5-yl)-6-chloro-N-(cyclopropylmethyl)imidazo[1,2-b]pyridazin-8-amine |
| SMILES | Cn1c(Nc2ccccc2)nc2ccc(-c3cnc4c(NCC5CC5)cc(Cl)nn34)cc21 |
| InChI | InChI=1S/C24H22ClN7/c1-31-20-11-16(9-10-18(20)29-24(31)28-17-5-3-2-4-6-17)21-14-27-23-19(26-13-15-7-8-15)12-22(25)30-32(21)23/h2-6,9-12,14-15,26H,7-8,13H2,1H3,(H,28,29) |
| InChIKey | APBYJKKXNBODGN-UHFFFAOYSA-N |
| XLogP | 5.50 |
| TPSA | 72.07 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 443.94 |
| LogP ≤ 5 | 5.50 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155560538 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.